Design, synthesis and mechanistic anticancer activity of new acetylated 5-aminosalicylate-thiazolinone hybrid derivatives

Tools

RAMADAN, Wafaa S., SABER-AYAD, Maha M., SALEH, Ekram, ABDU-ALLAH, Hajjaj H.M., EL-SHORBAGI, Abdel-nasser A., MENON, Varsha, TARAZI, Hamadeh, SEMREEN, Mohammad H., SOARES, Nelson C., HAFEZI, Shirin, VENKATAKHALAM, Thenmozhi, AHMED, Samrein, KANIE, Osamu, HAMOUDI, Rifat and EL-AWADY, Raafat (2024). Design, synthesis and mechanistic anticancer activity of new acetylated 5-aminosalicylate-thiazolinone hybrid derivatives. iScience, 27 (1): 108659. [Article]

[+][-]

Documents

32929:635164

[+][-]

32929:635164

[thumbnail of Ahmed-DesignSynthesisMechanistic(VoR).pdf]

Preview

PDF
Ahmed-DesignSynthesisMechanistic(VoR).pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (7MB) | Preview

Abstract

The development of hybrid compounds has been widely considered as a promising strategy to circumvent the difficulties that emerge in cancer treatment. The well-established strategy of adding acetyl groups to certain drugs has been demonstrated to enhance their therapeutic efficacy. Based on our previous work, an approach of accommodating two chemical entities into a single structure was implemented to synthesize new acetylated hybrids (HH32 and HH33) from 5-aminosalicylic acid and 4-thiazolinone derivatives. These acetylated hybrids showed potential anticancer activities and distinct metabolomic profile with antiproliferative properties. The in-silico molecular docking predicts a strong binding of HH32 and HH33 to cell cycle regulators, and transcriptomic analysis revealed DNA repair and cell cycle as the main targets of HH33 compounds. These findings were validated using in vitro models. In conclusion, the pleiotropic biological effects of HH32 and HH33 compounds on cancer cells demonstrated a new avenue to develop more potent cancer therapies.

More Information

Official URL:

https://www.sciencedirect.com/science/article/pii/...

Open Access URL:

https://www.sciencedirect.com/science/article/pii/...

Open Access Version:

Published version

Additional Information:

** Article version: VoR ** From Elsevier via Jisc Publications Router ** Licence for VoR version of this article starting on 04-12-2023: http://creativecommons.org/licenses/by-nc-nd/4.0/ **Journal IDs: issn 25890042 **History: issued 19-01-2024; published_online 27-12-2023; accepted 04-12-2023

Identifiers

Identification Number:

10.1016/j.isci.2023.108659

ORCID for Samrein Ahmed: